Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $54.94 Consensus Target Price from Analysts

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have earned an average recommendation of “Moderate Buy” from the eighteen ratings firms that are covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $54.94.

NTLA has been the subject of a number of research analyst reports. Chardan Capital lifted their price target on Intellia Therapeutics from $88.00 to $91.00 and gave the stock a “buy” rating in a report on Monday, November 18th. The Goldman Sachs Group decreased their price objective on shares of Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Oppenheimer reduced their target price on shares of Intellia Therapeutics from $70.00 to $60.00 and set an “outperform” rating for the company in a report on Monday, November 11th. Stifel Nicolaus lowered their price target on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a report on Wednesday, September 11th. Finally, Barclays reduced their price objective on Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating for the company in a report on Friday, November 8th.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA opened at $12.47 on Friday. The stock’s 50-day simple moving average is $14.01 and its 200 day simple moving average is $19.28. Intellia Therapeutics has a 52-week low of $11.34 and a 52-week high of $34.87. The company has a market cap of $1.27 billion, a P/E ratio of -2.29 and a beta of 1.83.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.37) by $0.03. The company had revenue of $9.10 million for the quarter, compared to analyst estimates of $8.28 million. The firm’s revenue for the quarter was down 24.1% compared to the same quarter last year. During the same period last year, the firm earned ($1.38) EPS. As a group, equities analysts predict that Intellia Therapeutics will post -5.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO John M. Leonard sold 26,807 shares of the stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the sale, the chief executive officer now owns 941,115 shares of the company’s stock, valued at $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold 28,735 shares of company stock valued at $349,909 over the last 90 days. 3.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Intellia Therapeutics

A number of large investors have recently modified their holdings of NTLA. EverSource Wealth Advisors LLC boosted its holdings in shares of Intellia Therapeutics by 763.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock valued at $39,000 after purchasing an additional 1,550 shares in the last quarter. Eastern Bank acquired a new stake in shares of Intellia Therapeutics in the 3rd quarter valued at $41,000. Values First Advisors Inc. acquired a new stake in shares of Intellia Therapeutics in the 3rd quarter valued at $54,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Intellia Therapeutics by 27.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock valued at $77,000 after purchasing an additional 794 shares in the last quarter. Finally, KBC Group NV boosted its holdings in shares of Intellia Therapeutics by 37.3% in the 3rd quarter. KBC Group NV now owns 3,753 shares of the company’s stock valued at $77,000 after purchasing an additional 1,020 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.